Top-Analysts PicksInvest alongside the top 15% of Wall Street analysts.

Try Top-Picks
Nuvation Bio Inc. Banner

Nuvation Bio Inc.

NUVB Stock Analysis

Page title

Section title

About Nuvation Bio Inc.

Biotechnology
Healthcare

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6...

Nuvation Bio Inc. Key Metrics

Market Cap
$740M
52 Weeks Low
$0.95
52 Weeks High
$4.16
P/B
2.84x
P/E
-1.43x
P/S
435.42x

Upcoming Events

    NUVB Analyst Forecasts

    ‌
    ‌

    NUVB Financials

    NUVB Income Statement Key Metrics

    • Revenue(TTM)1.70 M
    • Gross Profit(TTM)-60,000
    • EBITDA(TTM)-112.67 M
    • Net Income(TTM)-510.72 M
    • EPS Diluted(TTM)-2.1102000000000003

    Decode NUVB's Latest Earnings Call with Ease

    Tap 'Generate' for a crystal-clear,
    AI-crafted summary and stay ahead in the investment game!

    NUVB earnings and revenue history

    NUVB Return on Equity

    See how efficiently NUVB generates profit for it's shareholders.

    -12.53%

    10
    0
    100

    1. Poor

    2. Average

    3. Strong

    Return on Equity vs Peers

    Return on Equity ratio of NUVB (-0.125) is higher than the average of its peers (-0.489).

    Return on Equity Growth

    NUVB's Return on Equity has grown significantly over the past 10 years, increasing by over 32.58%.

    NUVB Revenue Growth

    See how NUVB has grown it's revenue over the past 10 years.

    ‌

    Revenue Growth

    NUVB's revenue has shown poor growth over the past 10 years, increasing by only 0%.